Equillium

$4.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.20%) Today

+$0.05 (+1.02%) As of 5:12 AM EST after-hours

Why Robinhood?

You can buy or sell Equillium and other stocks, options, and ETFs commission-free!

About EQ

Equillium, Inc. Common Stock, also called Equillium, is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA. The listed name for EQ is Equillium, Inc. Common Stock.

CEO

Bruce D. Steel

Employees

Headquarters

La Jolla, California

Founded

2017

Market Cap

121.66M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.04M

High Today

$5.03

Low Today

$4.83

Open Price

$4.88

Volume

438.62K

52 Week High

$27.05

52 Week Low

$2.20

Collections

EQ News

MarketWatchNov 25

Equillium's stock tumbles after decision to not initiate late-stage trial of COVID-19 treatment

Shares of Equillium Inc. EQ, -3.04% tumbled 12.6% in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 tria

EQ Earnings

-$0.45

-$0.30

-$0.15

-$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 25, After Hours